Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Enzon Pharmaceuticals ( (ENZN) ) just unveiled an announcement.
On December 23, 2025, Enzon Pharmaceuticals, Inc. executed a Sixth Amendment to its Section 382 Rights Agreement with Continental Stock Transfer & Trust Company, extending the Final Expiration Date of the rights issued under that agreement from December 31, 2025 to January 31, 2026. This latest amendment follows a series of prior date changes made between 2021 and 2025 and leaves all other terms of the Rights Agreement unchanged, reflecting management’s view that keeping the rights plan in place through January 31, 2026 is in the best interests of the company and its shareholders, with implications for the ongoing protection of its capital structure and tax-related benefits.
More about Enzon Pharmaceuticals
Enzon Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company that operates in the pharmaceutical industry, focusing on the development and management of drug-related assets and associated shareholder value. The company’s activities are closely tied to capital markets and corporate governance mechanisms designed to protect its tax assets and equity structure.
Average Trading Volume: 60,203
Technical Sentiment Signal: Sell
Current Market Cap: $3.27M
For detailed information about ENZN stock, go to TipRanks’ Stock Analysis page.